Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus Publisher Pubmed

Mahmoudi H¹ ; Toosi R¹ ; Salehifarid A¹ ; Daneshpazhooh M¹

Source: Oral Diseases Published:2023

Abstract

Over the past few decades, a number of scoring instruments have been developed to assess the severity and activity of autoimmune bullous diseases (AIBDs) (Daneshpazhooh et al., 2019; Nili et al., 2020; Nili et al., 2021; Nili et al., 2022). The Pemphigus Disease Area Index (PDAI), developed by the International Pemphigus Definitions Group, is an easy-to-use, quick, and reliable method for determining pemphigus severity. As a reliable and effective tool in clinical trials, PDAI may also have some limitations and might require some revisions to be used on a daily basis. Here, we propose some recommendations to improve the use of PDAI in the clinical setting. © 2023 Wiley Periodicals LLC.

Related Docs

View other Related Docs

1. Factors Associated With the Healing Time of Pemphigus Vulgaris Oral Lesions: A Prospective Study, Oral Diseases (2023)

2. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)

3. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (19)

Hamid Reza Mahmoodi (14)

Other Related Docs

4. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)

5. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)

6. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)

7. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)

8. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)

9. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)

10. Odss Vs. Absis and Pdai Oral Parts in Pemphigus Vulgaris: Inter-Rater Reliability and Testing Times, Oral Diseases (2023)

11. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)

12. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)

13. Pemphigus Patients With Initial Negative Levels of Anti-Desmoglein: A Subtype With Different Profile?, Dermatologic Therapy (2022)

14. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)

15. A Systematic Review on Efficacy, Safety and Treatment Durability of Intravenous Immunoglobulin in Autoimmune Bullous Dermatoses: Special Focus on Indication and Combination Therapy, Experimental Dermatology (2023)

16. Serologic Biomarkers in Pemphigus Monitoring: C-Reactive Protein, Macrophage Migration Inhibitory Factor, and Prolactin Levels Versus Autoantibody Assays, Iranian Journal of Allergy# Asthma and Immunology (2023)

17. Autoimmune Bullous Disease Quality of Life (Abqol) Questionnaire: Validation of the Translated Persian Version in Pemphigus Vulgaris, International Journal of Women's Dermatology (2020)

18. Pemphigus Scalp Lesions: Is Trichoscopy Helpful in Clinical Diagnosis?, International Journal of Dermatology (2021)

19. Assessing Quality of Life in Patients With Autoimmune Bullous Diseases Using the Persian Version of Treatment of Autoimmune Bullous Disease Quality of Life Questionnaire Finds Similar Effects in Women As Men, International Journal of Women's Dermatology (2022)

20. Are Sites of Primary Lesions in Pemphigus Vulgaris More Prone to Relapse?, Oral Diseases (2024)

Style	Citing Format
MLA	Mahmoudi H, et al.. "Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus." Oral Diseases, vol. , no. , 2023, pp. -.
APA	Mahmoudi H, Toosi R, Salehifarid A, Daneshpazhooh M (2023). Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus. Oral Diseases, (), -.
Chicago	Mahmoudi H, Toosi R, Salehifarid A, Daneshpazhooh M. "Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus." Oral Diseases , no. (2023): -.
Harvard	Mahmoudi H et al. (2023) 'Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus', Oral Diseases, (), pp. -.
Vancouver	Mahmoudi H, Toosi R, Salehifarid A, Daneshpazhooh M. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus. Oral Diseases. 2023;():-.
BibTex	@article{ author = {Mahmoudi H and Toosi R and Salehifarid A and Daneshpazhooh M}, title = {Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus}, journal = {Oral Diseases}, volume = {}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Mahmoudi H AU - Toosi R AU - Salehifarid A AU - Daneshpazhooh M TI - Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus JO - Oral Diseases VL - IS - SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Abstract